Trius' tedizolid for ABSSSI: non-inferior to Pfizer's Zyvox in Phase III trial
20 December 2011
Nancy Faigen
Please Login to read the full article.
20 December 2011
Nancy Faigen
nancy.faigen@informasua.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Bayer licenses non-US/EU rights to Trius' torezolid for $25M up front
- Positive Phase III results confirm Q2 2012 filing for Gilead's HIV drug booster, cobicistat
- Trius raises $30m to advance PhIII candidate torezolid for skin infections
- US FDA OK's revised labelling for Merck's Isentress
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
